Cargando…

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers

BACKGROUND: In healthy BRCA1/2 mutation carriers, bilateral risk-reducing mastectomy (BRRM) strongly reduces the risk of developing breast cancer (BC); however, no clear survival benefit of BRRM over BC surveillance has been reported yet. METHODS: In this Dutch multicenter cohort study, we used mult...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heemskerk-Gerritsen, Bernadette A. M., Jager, Agnes, Koppert, Linetta B., Obdeijn, A. Inge-Marie, Collée, Margriet, Meijers-Heijboer, Hanne E. J., Jenner, Denise J., Oldenburg, Hester S. A., van Engelen, Klaartje, de Vries, Jakob, van Asperen, Christi J., Devilee, Peter, Blok, Marinus J., Kets, C. Marleen, Ausems, Margreet G. E. M., Seynaeve, Caroline, Rookus, Matti A., Hooning, Maartje J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745043/ https://www.ncbi.nlm.nih.gov/pubmed/31302855 http://dx.doi.org/10.1007/s10549-019-05345-2

Ejemplares similares

Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study
por: Akdeniz, Delal, et al.
Publicado: (2021)

Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study
por: van Barele, Mark, et al.
Publicado: (2022)

Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study
por: de Jonge, Marthe M, et al.
Publicado: (2021)

Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers
por: Derks-Smeets, Inge A. P., et al.
Publicado: (2018)

Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study
por: Wevers, M. R., et al.
Publicado: (2015)

Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age
por: Drooger, Jan C., et al.
Publicado: (2015)

Progression-free survival and overall survival after BRCA1/2-associated epithelial ovarian cancer: A matched cohort study
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2022)

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
por: Drooger, Jan C., et al.
Publicado: (2016)

A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example
por: Mohammadi, Leila, et al.
Publicado: (2009)

Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2
por: Oldenburg, RA, et al.
Publicado: (2005)

A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history
por: Gómez García, Encarna B, et al.
Publicado: (2009)

The functional impact of variants of uncertain significance in BRCA2
por: Mesman, Romy L. S., et al.
Publicado: (2018)

Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy
por: Schmidt, MK, et al.
Publicado: (2005)

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers
por: van Sprundel, T C, et al.
Publicado: (2005)

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers
por: Mavaddat, Nasim, et al.
Publicado: (2020)

Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers
por: Mavaddat, Nasim, et al.
Publicado: (2020)

Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI
por: Veltman, J., et al.
Publicado: (2008)

Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2
por: Mesman, Romy L. S., et al.
Publicado: (2020)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

Correction: Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2
por: Mesman, Romy L. S., et al.
Publicado: (2020)

Contralateral breast cancer risk in patients with breast cancer and a germline-BRCA1/2 pathogenic variant undergoing radiation
por: van Barele, Mark, et al.
Publicado: (2023)

High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors
por: Stroot, Iris A.S., et al.
Publicado: (2023)

Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer
por: Verhoog, L C, et al.
Publicado: (2000)

Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)
por: Pijpe, Anouk, et al.
Publicado: (2012)

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up
por: Olivier, R I, et al.
Publicado: (2004)

Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2007)

Estrogen receptor transcription and transactivation: Genetic modifiers of cancer risks conferred by BRCA1 and BRCA2
por: Devilee, P
Publicado: (2001)

Screening for BRCA2 mutations in 81 Dutch breast–ovarian cancer families
por: Peelen, T, et al.
Publicado: (2000)

Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies
por: Gonzalez-Neira, Anna, et al.
Publicado: (2007)

Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
por: Phillips, KA, et al.
Publicado: (2012)

Exome Sequencing of Germline DNA from Non-BRCA1/2 Familial Breast Cancer Cases Selected on the Basis of aCGH Tumor Profiling
por: Hilbers, Florentine S., et al.
Publicado: (2013)

The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers
por: Obdeijn, Inge-Marie, et al.
Publicado: (2020)

Whole Exome Sequencing Suggests Much of Non-BRCA1/BRCA2 Familial Breast Cancer Is Due to Moderate and Low Penetrance Susceptibility Alleles
por: Gracia-Aznarez, Francisco Javier, et al.
Publicado: (2013)

Clustering of known low and moderate risk alleles rather than a novel recessive high‐risk gene in non‐BRCA1/2 sib trios affected with breast cancer
por: Hilbers, Florentine S., et al.
Publicado: (2020)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers
por: Qian, Frank, et al.
Publicado: (2019)

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2
por: Osorio, A, et al.
Publicado: (2011)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML
por: Hart, Steven N., et al.
Publicado: (2020)

Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study)
por: Terra, Lara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rfvl643ue951fsq00o9e8u1prv